DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Three New Methods for Diagnosing Pancreas Cancer

Information source: University of Copenhagen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pancreas Cancer

Intervention: Ultrasound and contrast agent (Procedure)

Phase: N/A

Status: Recruiting

Sponsored by: University of Copenhagen

Official(s) and/or principal investigator(s):
Michael B Nielsen, DMSc, Principal Investigator, Affiliation: Department of Radiology, Section of Ultrasound

Overall contact:
Hanne S Grossjohann, MD, Phone: +45 35453419, Email: hannesonder@dadlnet.dk

Summary

The purpose of this project is to evaluate and compare three new methods for diagnosis, staging, operability evaluation and treatment control of pancreas cancer. The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas. The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue, however, not in tumor tissue. The investigators hope to be able to use this effect diagnostically. The patients included will also have a 64-slice-CT in order to evaluate, if an increased diagnostic safety can be reached compared to an older CT scanning method. All patients will also be examined for the tumor marker CA 19-9. Further, the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment.

Clinical Details

Official title: Ultrasound With Contrast Agent, 64-Slice-CT and Tumormarkers for Diagnosing, Evaluation of Operability and Treatment Control of Pancreas Cancer

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- suspicion of cancer of the pancreas

Locations and Contacts

Hanne S Grossjohann, MD, Phone: +45 35453419, Email: hannesonder@dadlnet.dk

Copenhagen University Hospital, Copenhagen 2100, Denmark; Recruiting
Hanne S Grossjohann, MD, Phone: +45 35453419, Email: hannesonder@dadlnet.dk
Hanne S Grossjohann, MD, Principal Investigator
Additional Information

Starting date: February 2005
Last updated: February 25, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017